Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Inclusion Criteria: * SCREENING INCLUSION CRITERIA * Participant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG) after completing standard therapy * Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of the initial radiation therapy * Karnofsky performance status (KPS) \>= 60% * Life expectancy \> 4 weeks * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately * City of Hope (COH) Clinical Pathology confirms IL13R alpha 2+ tumor expression by immunohistochemistry (\>= 20%, 1+) * All research participants must have the ability to understand and the willingness to sign a written informed consent * ELIGIBILITY TO PROCEED WITH PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) COLLECTION * Research participant must not require more than 2 mg three times daily (TID) of dexamethasone on the day of PBMC collection. * Research participant must have appropriate venous access * At least 2 weeks must have elapsed since the research parti…